Evaxion Biotech A/S - ADR
EVAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.66M
Close$
$-0.33
110.2% downside
Current Fair Value
110.2% downsideOvervalued by 110.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.66 Million |
|---|---|
| Enterprise Value | $13.76 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.21 |
| Beta | 0.27 |
| Outstanding Shares | 417,010 |
Return
| Return on Equity | -91.13% |
|---|---|
| Return on Assets | -44.82% |
| Return on Invested Capital | -66.33% |
Valuation & Multiples
| P/E Ratio | -0.53 |
|---|---|
| PEG | 2.33 |
| Price to Sales | 0.18 |
| Price to Book Ratio | 0.15 |
| Enterprise Value to Revenue | 1.83 |
| Enterprise Value to EBIT | -1.28 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.52 |
| Debt to Equity | 0.75 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$6.70 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$300,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 381.81%▲ 303.01% |
|---|---|
| Total Invested | $4.94M▲ 303.78% |
| Investors Holding | 19▲ 4.00% |
ESG Score
No data
About Evaxion Biotech A/S
2,020 employeesEvaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immu...